Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy Combined with Radiotherapy and Sorafenib for Advanced Hepatocellular Carcinoma Patients with Major Portal Vein Tumor Thrombosis
- 9 February 2018
- journal article
- research article
- Published by S. Karger AG in Oncology
- Vol. 94 (4), 215-222
- https://doi.org/10.1159/000486483
Abstract
Objective: To compare the outcome of hepatic arterial infusion chemotherapy combined with radiotherapy (HAIC + RT) versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma (HCC) and major portal vein tumor thrombosis (PVTT). Methods: This retrospective study included 108 HCC patients with PVTT of the main trunk or first branch and Child-Pugh ≤7. Sixty-eight received HAIC + RT and 40 received sorafenib. Patients were then assigned to the HAIC + RT group (n = 36) and the sorafenib group (n = 36) through case-control matching. The decision to treat with HAIC + RT or sorafenib was left to the attending physician. Results: The median overall, progression-free, and postprogression survival were significantly longer in the HAIC + RT group than in the sorafenib group (9.9 vs. 5.3, p = 0.002; 3.9 vs. 2.1, p = 0.048; and 3.7 vs. 1.9 months, p = 0.02, respectively). Multivariate analysis identified HAIC + RT (hazard ratio = 2.02; 95% confidence interval, 1.14–3.57; p = 0.01) as a significant and independent determinant of overall survival. Conclusions: In patients with advanced HCC and major PVTT, survival was significantly longer in those treated with HAIC + RT than with sorafenib.This publication has 22 references indexed in Scilit:
- Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trialJournal of Hepatology, 2012
- Portal hemodynamic effects of sorafenib in patients with advanced hepatocellular carcinoma: a prospective cohort studyThe Esophagus, 2012
- Arterial-phase contrast-enhanced ultrasonography for evaluating anti-angiogenesis treatment: A pilot studyWorld Journal of Gastroenterology, 2011
- Intra-arterial 5-fluorouracil/interferon combination therapy for advanced hepatocellular carcinoma with or without three-dimensional conformal radiotherapy for portal vein tumor thrombosisThe Esophagus, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Similar effects of recombinant interferon‐α‐2b and natural interferon‐α when combined with intra‐arterial 5‐fluorouracil for the treatment of advanced hepatocellular carcinomaLiver International, 2007
- Patterns of Cancer Incidence, Mortality, and Prevalence Across Five Continents: Defining Priorities to Reduce Cancer Disparities in Different Geographic Regions of the WorldJournal of Clinical Oncology, 2006
- Combination therapy of intraarterial 5‐fluorouracil and systemic interferon‐alpha for advanced hepatocellular carcinoma with portal venous invasionCancer, 2006
- Management of hepatocellular carcinoma in JapanThe Esophagus, 2006
- Hepatic arterial infusion of 5‐fluorouracil and cisplatin for unresectable or recurrent hepatocellular carcinoma with tumor thrombus of the portal veinJournal of Surgical Oncology, 2002